Emergent reports financial results and accomplishments for Q2 2013
Emergent's total revenue for the second quarter was up from $70.4 million in 2012 to $82.4 million in 2013. Total revenues for the first six months of 2013 rose to $125.5 million from $120.7 million during the same time period last year.
Daniel Abdun-Nabi, the company's president and CEO, said the company was pleased with its performance and operational achievements.
"We are very pleased with our performance for the second quarter and year-to-date," Abdun-Nabi said. "We achieved strong financial results and significantly advanced our operational objectives, including closing on the Healthcare Protective Products Division of Bracco Diagnostics, Inc., securing German approval of BioThrax with a three-dose primary series and triennial boosters, and continuing to progress our biodefense and biosciences development programs. We are well positioned to continue to deliver financial results in accordance with our forecast and to execute on our growth plan."
During the second quarter of 2013, Emergent also completed a Phase III clinical study evaluating the safety and immunogenicity of a three-dose BioThrax regimen for the post-exposure prophylaxis indication, completed enrollment in an important antibiotic non-interference trial in support of the PEP indication for BioThrax and presented preclinical efficacy data on ES210, a bispecific ADAPTIR molecule in development for the treatment of autoimmune diseases.